The Non-Malignant Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ISTH 2024 | An overview of ongoing clinical trials for the treatment of hemophilia
In this video, Omolade Awodu, MBChB, MD, FMCPath, University of Benin, Benin City, Nigeria, gives an overview of some of the most exciting clinical trials taking place in hemophilia. The Phase III Explorer8 study (NCT04082429), which is exploring the use of concizumab for patients with hemophilia A and B, has shown reduced median annualized bleeding rates (ABRs) for this agent compared to standard therapy. Prof. Awodu also highlights that there are many promising clinical trials being conducted on fitusiran, an RNA interference agent, and in gene therapies. This interview took place at the 32nd Congress of the International Society on Thrombosis and Haemostasis (ISTH), held in Bangkok, Thailand, and virtually.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
